academic article

• Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial..  Lancet neurology.  19:988-997. 2020
• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis..  The New England journal of medicine.  376:221-234. 2017
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis..  The New England journal of medicine.  376:209-220. 2017
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial..  Lancet.  380:1829-1839. 2012
• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial..  Lancet.  380:1819-1828. 2012
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study..  Lancet neurology.  8:889-897. 2009